Medicaid Cuts Trans Youth Hormone Coverage for Under-19s by April 2027

For healthcare professionals, this policy will reshuffle coverage and care pathways for transgender minors: surgeries are rare, but puberty blockers and hormone treatments are more common, and the April 2027 phase-out creates a clinical transition window for patients already in treatment.

On August 11, 2026, the Trump administration announced that federal Medicaid and the Children’s Health Insurance Program will stop paying for gender-affirming surgeries and hormone treatments for transgender minors, with the policy taking effect October 13, 2026. The decision, announced by CMS under administrator Dr. Mehmet Oz at Trump’s direction, is the latest in a series of restrictions on transgender-related health care since Trump returned to office on January 20, 2025. Under the new rule, CHIP will no longer cover the treatments for people under age 19, while Medicaid and CHIP will continue to pay for mental health services for transgender minors. Patients already receiving covered hormone treatments will have a transition period before federal funding is phased out in April 2027.

“

Under the new rule, CHIP will no longer cover the treatments for people under age 19, while Medicaid and CHIP will continue to pay for mental health services for transgender minors.

The federal directive lands amid a deeply fragmented state landscape. At least 27 states have already enacted bans on gender-affirming care for people under 18, and even in states without statutory bans many major hospitals have stopped providing some treatments. The practical effect of the federal policy is therefore uneven: in states that already restrict care, the change is largely consistent with existing state law; in states that still permit such care, the loss of federal reimbursement creates new financial and operational pressure on providers and families. Importantly, gender-affirming surgeries for minors are rare; puberty blockers and hormone treatments are more common, meaning the hormone phase-out is likely to have the broader clinical and administrative impact.

The administration has not specified how much federal taxpayer funding currently goes to these treatments. The Centers for Medicare and Medicaid Services did not respond to questions from the Associated Press seeking additional information, leaving the fiscal significance of the policy unclear. That absence of data may matter in both the political and legal arenas. Trump framed the change on Truth Social as protecting children from what he called barbaric and irreversible practices, while LGBTQ+ advocates argued the policy interferes with families’ ability to make medical decisions with professionals. Josh Rovenger, legal director for GLBTQ Legal Advocates and Defenders, said the rule is putting up barriers between parents and their ability to make the best medical decisions for their children and would face a legal challenge. Human Rights Campaign President Kelley Robinson said the administration is terrorizing trans youth and their families.

From a legal and regulatory perspective, the policy raises significant questions. Medicaid is a federal-state partnership, and conditioning federal funds on the exclusion of specific medical treatments for a defined class of minors implicates federal preemption, equal protection, parental rights, and potentially the Administrative Procedure Act. The impending litigation signaled by GLAD will likely test whether the administration can use funding conditions to override clinical standards and state choices, and whether the policy is arbitrary or discriminatory. The timeline—announcement in August, effective date in October, and phase-out in April 2027—also creates a window for courts to intervene before the funding cliff fully materializes.